These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

232 related articles for article (PubMed ID: 28521651)

  • 61. CT Features of Epidermal Growth Factor Receptor-Mutated Adenocarcinoma of the Lung: Comparison with Nonmutated Adenocarcinoma.
    Hasegawa M; Sakai F; Ishikawa R; Kimura F; Ishida H; Kobayashi K
    J Thorac Oncol; 2016 Jun; 11(6):819-26. PubMed ID: 26917231
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Different spatial distributions of brain metastases from lung cancer by histological subtype and mutation status of epidermal growth factor receptor.
    Takano K; Kinoshita M; Takagaki M; Sakai M; Tateishi S; Achiha T; Hirayama R; Nishino K; Uchida J; Kumagai T; Okami J; Kawaguchi A; Hashimoto N; Nakanishi K; Imamura F; Higashiyama M; Yoshimine T
    Neuro Oncol; 2016 May; 18(5):716-24. PubMed ID: 26519739
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Dynamic Contrast-enhanced MR Imaging Parameters in Bone Metastases from Non-Small Cell Lung Cancer: Comparison between Lesions with and Lesions without Epidermal Growth Factor Receptor Mutation in Primary Lung Cancer.
    Kim HS; Yoon YC; Kwon S; Lee JH; Ahn S; Ahn HS
    Radiology; 2017 Sep; 284(3):815-823. PubMed ID: 28448232
    [TBL] [Abstract][Full Text] [Related]  

  • 64. EGFR mutation frequency and effectiveness of erlotinib: a prospective observational study in Danish patients with non-small cell lung cancer.
    Weber B; Hager H; Sorensen BS; McCulloch T; Mellemgaard A; Khalil AA; Nexo E; Meldgaard P
    Lung Cancer; 2014 Feb; 83(2):224-30. PubMed ID: 24388704
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Brain Metastases in NSCLC - are TKIs Changing the Treatment Strategy?
    Dempke WC; Edvardsen K; Lu S; Reinmuth N; Reck M; Inoue A
    Anticancer Res; 2015 Nov; 35(11):5797-806. PubMed ID: 26504000
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Baseline and Trend of Lymphocyte-to-Monocyte Ratio as Prognostic Factors in Epidermal Growth Factor Receptor Mutant Non-Small Cell Lung Cancer Patients Treated with First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
    Chen YM; Lai CH; Chang HC; Chao TY; Tseng CC; Fang WF; Wang CC; Chung YH; Wang YH; Su MC; Huang KT; Chen HC; Chang YC; Lin MC
    PLoS One; 2015; 10(8):e0136252. PubMed ID: 26313661
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Frequency and outcomes of brain metastases in patients with HER2-mutant lung cancers.
    Offin M; Feldman D; Ni A; Myers ML; Lai WV; Pentsova E; Boire A; Daras M; Jordan EJ; Solit DB; Arcila ME; Jones DR; Isbell JM; Beal K; Young RJ; Rudin CM; Riely GJ; Drilon A; Tabar V; DeAngelis LM; Yu HA; Kris MG; Li BT
    Cancer; 2019 Dec; 125(24):4380-4387. PubMed ID: 31469421
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Isolated Brain Metastases as the First Relapse After the Curative Surgical Resection in Non-Small-Cell Lung Cancer Patients With an EGFR Mutation.
    Sadoyama S; Sekine A; Satoh H; Iwasawa T; Kato T; Ikeda S; Sata M; Baba T; Tabata E; Minami Y; Nemoto K; Hayashihara K; Saito T; Okudela K; Ohashi K; Tajiri M; Ogura T
    Clin Lung Cancer; 2018 Jan; 19(1):e29-e36. PubMed ID: 28669848
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Multidisciplinary expert opinion on the treatment consensus for patients with EGFR mutated NSCLC with brain metastases.
    Ponce S; Bruna J; Juan O; López R; Navarro A; Ortega AL; Puente J; Verger E; Bartolomé A; Nadal E
    Crit Rev Oncol Hematol; 2019 Jun; 138():190-206. PubMed ID: 31092376
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Frequency of brain metastases in non-small-cell lung cancer, and their association with epidermal growth factor receptor mutations.
    Iuchi T; Shingyoji M; Itakura M; Yokoi S; Moriya Y; Tamura H; Yoshida Y; Ashinuma H; Kawasaki K; Hasegawa Y; Sakaida T; Iizasa T
    Int J Clin Oncol; 2015 Aug; 20(4):674-9. PubMed ID: 25336382
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Association of diffuse, random pulmonary metastases, including miliary metastases, with epidermal growth factor receptor mutations in lung adenocarcinoma.
    Togashi Y; Masago K; Kubo T; Sakamori Y; Kim YH; Hatachi Y; Fukuhara A; Mio T; Togashi K; Mishima M
    Cancer; 2011 Feb; 117(4):819-25. PubMed ID: 20886633
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Clinical characteristics of miliary pulmonary metastases in non-small cell lung cancer.
    Choi H; Im Y; Jeong BH; Lee K; Kim H; Um SW
    Thorac Cancer; 2023 Aug; 14(22):2168-2176. PubMed ID: 37337934
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Phosphorylated insulin-like growth factor-1 receptor (pIGF1R) is a poor prognostic factor in brain metastases from lung adenocarcinomas.
    Wu PF; Huang WC; Yang JC; Lu YS; Shih JY; Wu SG; Lin CH; Cheng AL
    J Neurooncol; 2013 Oct; 115(1):61-70. PubMed ID: 23817810
    [TBL] [Abstract][Full Text] [Related]  

  • 74. Systemic Treatment Options for Brain Metastases from Non-Small-Cell Lung Cancer.
    Bulbul A; Forde PM; Murtuza A; Woodward B; Yang H; Bastian I; Ferguson PK; Lopez-Diaz F; Ettinger DS; Husain H
    Oncology (Williston Park); 2018 Apr; 32(4):156-63. PubMed ID: 29684234
    [TBL] [Abstract][Full Text] [Related]  

  • 75. The predictive value and potential mechanisms of miRNA-328 and miRNA-378 for brain metastases in operable and advanced non-small-cell lung cancer.
    Sun D; Li X; Ma M; Liu J; Xu Y; Ye L; Hou H; Wang C; Li X; Jiang Y
    Jpn J Clin Oncol; 2015 May; 45(5):464-73. PubMed ID: 25646356
    [TBL] [Abstract][Full Text] [Related]  

  • 76. [Clinical Features of EGFR Mutation Negative in Patients 
with Non-small Cell Lung Cancer and Brain Metastases].
    Zhu Y; Zhang Y
    Zhongguo Fei Ai Za Zhi; 2021 Jan; 24(1):43-48. PubMed ID: 33478190
    [TBL] [Abstract][Full Text] [Related]  

  • 77. Imaging Pattern of Diffuse Intrapulmonary Metastases in Lung Cancer Was Associated with Poor Prognosis to Epidermal Growth Factor Receptor Inhibitors.
    Fu Y; Tang Y; Zheng Y; Chen YY; Hong Y; Wang PP; Li Q; Liu T; Ding ZY
    Cancer Manag Res; 2020; 12():11761-11772. PubMed ID: 33235504
    [TBL] [Abstract][Full Text] [Related]  

  • 78. Genomic signature for oligometastatic disease in non-small cell lung cancer patients with brain metastases.
    Choi AR; D'Agostino RB; Farris MK; Abdulhaleem M; Hunting JC; Wang Y; Smith MR; Ruiz J; Lycan TW; Petty WJ; Cramer CK; Tatter SB; Laxton AW; White JJ; Li W; Su J; Whitlow C; Xing F; Chan MD
    Front Endocrinol (Lausanne); 2024; 15():1364021. PubMed ID: 39355617
    [TBL] [Abstract][Full Text] [Related]  

  • 79. [Lung Adenocarcinomas with Pulmonary Miliary Metastases: A Case Report and Literature Review].
    Li L; Zhou L; Zhang J
    Zhongguo Fei Ai Za Zhi; 2019 Dec; 22(12):798-804. PubMed ID: 31874677
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Prognostic Significance of Sites of Visceral Metastatic Disease in Prostate Cancer: A Population-based Study of 12,180 Patients.
    Budnik J; Suri J; Bates JE; Bylund KC; Milano MT
    Clin Genitourin Cancer; 2019 Aug; 17(4):260-267. PubMed ID: 31101579
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.